RU2015137703A - Линии клеток для получения вирусов и способы их применения - Google Patents
Линии клеток для получения вирусов и способы их применения Download PDFInfo
- Publication number
- RU2015137703A RU2015137703A RU2015137703A RU2015137703A RU2015137703A RU 2015137703 A RU2015137703 A RU 2015137703A RU 2015137703 A RU2015137703 A RU 2015137703A RU 2015137703 A RU2015137703 A RU 2015137703A RU 2015137703 A RU2015137703 A RU 2015137703A
- Authority
- RU
- Russia
- Prior art keywords
- cell line
- cells
- mir
- virus
- expression
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims 17
- 108091026890 Coding region Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 108091070501 miRNA Proteins 0.000 claims 5
- -1 GLXP3 Proteins 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 108091062170 Mir-22 Proteins 0.000 claims 2
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 108091056875 miR-1256 stem-loop Proteins 0.000 claims 2
- 108091082217 miR-3187 stem-loop Proteins 0.000 claims 2
- 108091032623 miR-513a-1 stem-loop Proteins 0.000 claims 2
- 108091080923 miR-513a-2 stem-loop Proteins 0.000 claims 2
- 108091091625 miR-519c stem-loop Proteins 0.000 claims 2
- 108091042438 miR-519c-1 stem-loop Proteins 0.000 claims 2
- 108091086222 miR-520c stem-loop Proteins 0.000 claims 2
- 108091073864 miR-520d stem-loop Proteins 0.000 claims 2
- 108091070778 miR-520e stem-loop Proteins 0.000 claims 2
- 108091047084 miR-9 stem-loop Proteins 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102100027157 Butyrophilin subfamily 2 member A1 Human genes 0.000 claims 1
- 102100021897 Cyclin-P Human genes 0.000 claims 1
- 102100040890 Glucagon receptor Human genes 0.000 claims 1
- 101000984926 Homo sapiens Butyrophilin subfamily 2 member A1 Proteins 0.000 claims 1
- 101000897443 Homo sapiens Cyclin-P Proteins 0.000 claims 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 claims 1
- 101000958327 Homo sapiens Lymphocyte antigen 6 complex locus protein G6c Proteins 0.000 claims 1
- 101000581537 Homo sapiens Mitochondrial coiled-coil domain protein 1 Proteins 0.000 claims 1
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 claims 1
- 101001093143 Homo sapiens Protein transport protein Sec61 subunit gamma Proteins 0.000 claims 1
- 101000596092 Homo sapiens Transcription initiation factor TFIID subunit 1-like Proteins 0.000 claims 1
- 101000744929 Homo sapiens Zinc finger protein 205 Proteins 0.000 claims 1
- 102100038211 Lymphocyte antigen 6 complex locus protein G6c Human genes 0.000 claims 1
- 102100027319 Mitochondrial coiled-coil domain protein 1 Human genes 0.000 claims 1
- 102100035251 Protein C-ets-1 Human genes 0.000 claims 1
- 102100036306 Protein transport protein Sec61 subunit gamma Human genes 0.000 claims 1
- 102100035238 Transcription initiation factor TFIID subunit 1-like Human genes 0.000 claims 1
- 102100039959 Zinc finger protein 205 Human genes 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32051—Methods of production or purification of viral material
- C12N2770/32052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32651—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (30)
1. Сконструированная линия клеток, где клетки сконструированной линии клеток характеризуются пониженной экспрессией кодирующего участка, выбранного из таблицы I, по сравнению с контрольной линией клеток, где кодирующий участок выбирают из ZNF205, CNTD2, SEC61G, ETS1, TAF1L, MCCD1, LY6G6C, BTN2A1, GLXP3, GCGR, EP300.
2. Сконструированная линия клеток, где клетки сконструированной линии клеток характеризуются пониженной экспрессией кодирующего участка, выбранного из таблицы I, по сравнению с контрольной линией клеток.
3. Сконструированная линия клеток, где клетки сконструированной линии клеток характеризуются повышенной экспрессией кодирующего участка, выбранного из таблицы II, по сравнению с контрольной линией клеток.
4. Сконструированная линия клеток, где клетки сконструированной линии клеток характеризуются повышенной экспрессией miRNA, выбранной из miR-520e, miR-1256, miR-520d-3p, miR-513a-5p, miR-519c-3p, miR-1270-2, miR-3187, miR-5763p, miR-22, miR-520c-3p и miR-9, по сравнению с контрольной линией клеток.
5. Сконструированная линия клеток, где клетки сконструированной линии клеток характеризуются пониженной экспрессией эндогенной miRNA, выбранной из таблицы IV, по сравнению с контрольной линией клеток.
6. Лизат сконструированной линии клеток по пп. 1-5.
7. Способ получения вируса, включающий:
получение сконструированной линии клеток по пп. 1-5, где клетки линии клеток содержат вирус;
инкубирование сконструированной линии клеток при условиях, подходящих для продуцирования вируса клетками; и
сбор вируса, продуцированного клетками.
8. Способ получения вируса, включающий:
получение линии клеток, где клетки линии клеток содержат вирус;
инкубирование линии клеток при условиях, подходящих для продуцирования вируса клетками, где среда содержит полинуклеотид РНК, который подавляет экспрессию кодирующего участка, выбранного из таблицы I; и
сбор вируса, продуцированного клетками.
9. Способ получения вируса, включающий:
получение линии клеток, где клетки линии клеток содержат вирус, и где клетки содержат отредактированный геном, что приводит к пониженной экспрессии кодирующего участка, выбранного из таблицы I;
инкубирование линии клеток при условиях, подходящих для продуцирования вируса клетками; и
сбор вируса, продуцированного клетками.
10. Способ получения вируса, включающий:
получение линии клеток, где клетки линии клеток содержат вирус;
инкубирование линии клеток при условиях, подходящих для продуцирования вируса клетками, где среда содержит малую молекулу, которая подавляет экспрессию кодирующего участка, выбранного из таблицы I; и
сбор вируса, продуцированного клетками.
11. Способ получения сконструированной клетки, включающий:
введение в клетку молекулы для редактирования генома клетки;
инкубирование содержащей молекулу клетки при условиях, подходящих для того, чтобы произошло редактирование генома;
получение сконструированной клетки, содержащей отредактированный геном, где редактирование приводит к пониженной экспрессии кодирующего участка, выбранного из таблицы I, по сравнению с контрольной линией клеток.
12. Способ лечения пациента, характеризующегося наличием или повышенным риском приобретения вирусной инфекции, включающий повышение экспрессии кодирующего участка, выбранного из таблицы I, в клетках пациента.
13. Способ лечения пациента, характеризующегося наличием или повышенным риском приобретения вирусной инфекции, включающий подавление экспрессии кодирующего участка, выбранного из таблицы II, в клетках пациента.
14. Способ лечения пациента, характеризующегося наличием или повышенным риском приобретения вирусной инфекции, включающий подавление экспрессии эндогенной miRNA, выбранной из miR-520e, miR-1256, miR-520d-3p, miR-513a-5p, miR-519c-3p, miR-1270-2, miR-3187, miR-5763p, miR-22, miR-520c-3p и miR-9, в клетках пациента.
15. Способ лечения пациента, характеризующегося наличием или повышенным риском приобретения вирусной инфекции, включающий повышение экспрессии miRNA, выбранной из таблицы IV, в клетках пациента.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361760895P | 2013-02-05 | 2013-02-05 | |
| US61/760,895 | 2013-02-05 | ||
| US201361885357P | 2013-10-01 | 2013-10-01 | |
| US61/885,357 | 2013-10-01 | ||
| PCT/US2014/014813 WO2014123967A2 (en) | 2013-02-05 | 2014-02-05 | Cell lines for virus production and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015137703A true RU2015137703A (ru) | 2017-03-09 |
| RU2015137703A3 RU2015137703A3 (ru) | 2018-03-01 |
Family
ID=50159542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015137703A RU2015137703A (ru) | 2013-02-05 | 2014-02-05 | Линии клеток для получения вирусов и способы их применения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10137188B2 (ru) |
| EP (2) | EP2954055B1 (ru) |
| JP (1) | JP2016506734A (ru) |
| KR (1) | KR20150133695A (ru) |
| CN (2) | CN105121645B (ru) |
| AU (1) | AU2014215025B2 (ru) |
| BR (1) | BR112015018493A2 (ru) |
| CA (1) | CA2899928A1 (ru) |
| MX (1) | MX2015010017A (ru) |
| RU (1) | RU2015137703A (ru) |
| WO (1) | WO2014123967A2 (ru) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US9719094B2 (en) * | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| JP6730188B2 (ja) * | 2014-09-22 | 2020-07-29 | 国立研究開発法人科学技術振興機構 | インフルエンザウイルス産生用細胞、及びインフルエンザウイルスの産生方法 |
| US10883086B2 (en) | 2015-07-06 | 2021-01-05 | University Of Georgia Research Foundation, Inc. | Methods and compositions related to increased influenza virus production |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
| US10633662B2 (en) * | 2015-11-10 | 2020-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating AAV infection |
| AU2016361454A1 (en) | 2015-11-24 | 2018-06-21 | Commonwealth Scientific And Industrial Research Organisation | Production of viruses in avian eggs |
| CN108603188A (zh) | 2015-11-24 | 2018-09-28 | 联邦科学技术研究组织 | 在细胞培养物中产生病毒 |
| US20190100761A1 (en) * | 2016-04-06 | 2019-04-04 | Duke University | Compositions and methods for enhanced gene expression and viral replication |
| US11058760B2 (en) | 2016-04-18 | 2021-07-13 | University Of Florida Research Foundation, Incorporated | N-antigenic form poliovirus virus-like particles comprising thermostable mutations |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| JP7588390B2 (ja) | 2016-10-14 | 2024-11-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基エディターのａａｖ送達 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP4205760A1 (en) * | 2017-03-08 | 2023-07-05 | University of Georgia Research Foundation, Inc. | Methods and compositions related to increased viral production |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| BR112019019655A2 (pt) | 2017-03-23 | 2020-04-22 | Harvard College | editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| FR3067933B1 (fr) * | 2017-06-21 | 2020-07-17 | L'oreal | Modulateurs de l’opsine 3 dans la modulation de la pigmentation de la peau |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| MX2020001528A (es) * | 2017-08-14 | 2020-08-03 | Univ Georgia | Proteinas que tienen actividad de degradacion de la capsula neumococal y metodos de uso. |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019090020A1 (en) * | 2017-11-02 | 2019-05-09 | University Of Georgia Research Foundation, Inc. | Methods and compositions related to increased rotavirus production |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020000464A1 (zh) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | 一种制备gl-r基因敲除小鼠的方法 |
| EP3846862B1 (en) | 2018-09-07 | 2025-12-10 | The Procter & Gamble Company | Volatile composition dispenser |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942042A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020210507A1 (en) | 2019-04-12 | 2020-10-15 | Ultragenyx Pharmaceutical Inc. | Engineered producer cell lines and methods of making and using the same |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB240455A (en) | 1924-09-23 | 1926-12-16 | Siegmund Loewe | High frequency thermionic valve |
| US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
| RU2192884C2 (ru) | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
| ATE490321T1 (de) * | 2003-01-17 | 2010-12-15 | Max Planck Gesellschaft | Induzierbare sirna expressionskonstrukte zur gezielten genabschaltung |
| CN1548054A (zh) * | 2003-05-08 | 2004-11-24 | 陆爱丽 | 预防或治疗sars冠状病毒的药物 |
| US20090280567A1 (en) | 2004-02-06 | 2009-11-12 | Dharmacon, Inc. | Stabilized sirnas as transfection controls and silencing reagents |
| US20100035963A1 (en) * | 2005-09-09 | 2010-02-11 | Ayelet Chajut | Oligoribonucleotides and Methods of use Thereof for Treatment of Cardiovascular Disease |
| CN101622349A (zh) * | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为治疗性干预靶标的miR-21调节的基因和途径 |
| US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| CA2695505A1 (en) * | 2007-08-06 | 2009-02-12 | Burnham Institute For Medical Research | Znf206: a novel regulator of embryonic stem cell self-renewal and pluripotency |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| US20120039939A1 (en) * | 2008-04-11 | 2012-02-16 | The Johns Hopkins University | Compositions and methods for vaccine and virus production |
| PL2454364T3 (pl) * | 2009-07-16 | 2014-09-30 | Crucell Holland Bv | Produkcja wirusa polio o wysokim mianie do produkcji szczepionki |
-
2014
- 2014-02-05 EP EP14706395.2A patent/EP2954055B1/en not_active Not-in-force
- 2014-02-05 MX MX2015010017A patent/MX2015010017A/es unknown
- 2014-02-05 RU RU2015137703A patent/RU2015137703A/ru not_active Application Discontinuation
- 2014-02-05 EP EP18164513.6A patent/EP3372685A3/en not_active Withdrawn
- 2014-02-05 CN CN201480007578.8A patent/CN105121645B/zh not_active Expired - Fee Related
- 2014-02-05 JP JP2015556249A patent/JP2016506734A/ja active Pending
- 2014-02-05 CN CN201810357652.9A patent/CN108588027A/zh active Pending
- 2014-02-05 CA CA2899928A patent/CA2899928A1/en not_active Abandoned
- 2014-02-05 BR BR112015018493A patent/BR112015018493A2/pt active Search and Examination
- 2014-02-05 KR KR1020157020862A patent/KR20150133695A/ko not_active Withdrawn
- 2014-02-05 AU AU2014215025A patent/AU2014215025B2/en not_active Expired - Fee Related
- 2014-02-05 US US14/765,365 patent/US10137188B2/en not_active Expired - Fee Related
- 2014-02-05 WO PCT/US2014/014813 patent/WO2014123967A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20150374812A1 (en) | 2015-12-31 |
| HK1219975A1 (en) | 2017-04-21 |
| AU2014215025B2 (en) | 2018-08-30 |
| CN108588027A (zh) | 2018-09-28 |
| EP2954055B1 (en) | 2018-04-11 |
| EP3372685A2 (en) | 2018-09-12 |
| KR20150133695A (ko) | 2015-11-30 |
| WO2014123967A3 (en) | 2014-11-06 |
| RU2015137703A3 (ru) | 2018-03-01 |
| WO2014123967A2 (en) | 2014-08-14 |
| US10137188B2 (en) | 2018-11-27 |
| CN105121645A (zh) | 2015-12-02 |
| CA2899928A1 (en) | 2014-08-14 |
| CN105121645B (zh) | 2018-05-08 |
| US20170151322A9 (en) | 2017-06-01 |
| BR112015018493A2 (pt) | 2017-08-22 |
| EP2954055A2 (en) | 2015-12-16 |
| EP3372685A3 (en) | 2018-10-17 |
| MX2015010017A (es) | 2016-03-04 |
| AU2014215025A1 (en) | 2015-07-09 |
| JP2016506734A (ja) | 2016-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015137703A (ru) | Линии клеток для получения вирусов и способы их применения | |
| MX2022006854A (es) | Composiciones y metodos de arn circular. | |
| EA200801221A1 (ru) | Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк | |
| BR112018013808A2 (pt) | dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer | |
| MX385736B (es) | Medios y métodos de fermentación para producir polisacárido en cultivo celular bacteriano. | |
| BR112012000942B8 (pt) | processos para a produção de poliovírus, e para produzir uma vacina contra pólio | |
| MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
| EA201492014A1 (ru) | Получение ротавирус-подобных частиц в растениях | |
| PH12014500640A1 (en) | Increasing virus-like particle yield in plants | |
| DOP2010000251A (es) | Paramyxovirus eficaz como antitumoral | |
| BR112016028185A2 (pt) | método para produzir um l-aminoácido. | |
| BRPI0914805B8 (pt) | método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição | |
| PH12023550246A1 (en) | Modified chikungunya viruses and sindbis viruses and uses thereof | |
| MX2024012693A (es) | Composiciones y metodos para la prevencion y el tratamiento de la infeccion por el virus de la rabia | |
| AR107198A1 (es) | PROCESO DE PRODUCCIÓN DE UNA GONADOTROPINA CORIÓNICA EQUINA RECOMBINANTE (reCG); COMPOSICIÓN VETERINARIA Y USO | |
| BR112015021772A2 (pt) | método para a preparação de células embrionárias aviárias, método melhorado para a preparação de células embrionárias aviárias a partir de um embrião, cultura ou composição de células embrionárias aviárias, método para a produção ou amplificação de um vírus, e, composição de vacina | |
| MX2013012925A (es) | Metodos y composiciones para silenciar familias de genes mediante el uso de microarn artificiales. | |
| BR112022019647A2 (pt) | Vetores para produção de partículas semelhantes a vírus e usos das mesmas | |
| RU2011106732A (ru) | Способ диагностики немелкоклеточного рака легких, включая плоскоклеточный рак и аденокарциному, и пара праймеров для его осуществления | |
| WO2019227259A1 (zh) | 一种基于哺乳动物病毒的介导miRNA过表达方法 | |
| RU2012107641A (ru) | Стимулятор роста yersinia pseudotuberculosis | |
| BR112018069854A2 (pt) | métodos para produzir proteína, xilo-oligossacarídeos e glicose, método para suprimir a diminuição na saturação de oxigênio dissolvido ao cultivar um fungo e composição de celulase | |
| RU2014145911A (ru) | Способы воздействия на экспрессию гена BRCA2 | |
| RU2011105713A (ru) | Способ получения диплоидных клеток легкого плода буйволицы для культивирования вирусов | |
| RU2014142754A (ru) | Способы воздействия на экспрессию гена алкогольдегидрогеназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181206 |